Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.135    -0.015 (-10.00%)
Bid:
0.13
Ask:
0.14
Spread: 0.01 (7.692%)
Market Cap: £1.78m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Final Results

23 Jun 2005 14:42

AZURE HOLDINGS PLC PRELIMINARY ANNOUNCEMENT OF RESULTS YEAR ENDED 31 DECEMBER 2004 Chairman's StatementI am pleased to present my report for the year ended 31 December 2004.Your Company is still seeking a suitable merger target. During the period, theCompany entered into discussions with an acquisition target but the board couldnot agree commercial terms and talks were terminated.Your board is pursuing other acquisition targets which, owing to their size,may result in a reverse takeover.In the meantime, the directors have agreed not to draw their salaries and arefocused on keeping overheads to a minimum.Nicolas GreenstoneChairman23 June 2005Profit and loss accountfor the year ended 31 December 2004 Year ended Year ended 31 31 December December 2004 2003 ‚£'000 ‚£'000 Administrative expenses (345) (86) Profit on disposal of investments - 10 Operating loss (345) (76) Loss on disposal of subsidiary undertakings - (74) Loss on ordinary activities before taxation (345) (150) Taxation - - Loss on ordinary activities after taxation (345) (150) Loss per share (0.86p) (4.14p) Fully diluted loss per share (0.86p) (4.14p) The Group has no recognised gains and losses other than the loss for the year.Balance sheetas at 31 December 2004 2004 2003 ‚£'000 ‚£'000 Current assets Debtors 7 7 Cash at bank and in hand 14 119 21 126 Creditors: amounts falling due within one year (90) (59) Net current (liabilities)/assets (69) 67 Total assets less current liabilities (69) 67 Capital and reserves Called up share capital 5,475 5,304 Share premium account 10,279 10,241 Profit and loss account (15,823) (15,478) Equity shareholders' (deficit)/funds (69) 67 Cash flow statementfor the year ended 31 December 2004 2004 2003 ‚£'000 ‚£'000 Cash outflow from operating activities (225) (76) Financing Issue of equity shares 120 195 (Decrease)/increase in cash in the year (105) 119 Notes to the preliminary announcementfor the year ended 31 December 2004 1. Basis of preparation The financial information in this announcement does not constitute statutoryfinancial statements as defined in Section 240 of the Companies Act 1985. Theinformation relating to the year ended 31 December 2003 is an extract from thestatutory accounts for that year, which have been delivered to the Registrar ofCompanies. The auditors' report on those accounts was unqualified and did notcontain any statement under section 237(2) or (3) of the Companies Act 1985.The auditors have indicated that they will issue an unqualified report on thestatutory financial statements for the year ended 31 December 2004. Copies ofthe Company's Report and Financial Statements will be sent to shareholdersshortly and will be available at the registered office of the Company: OneGreat Cumberland Place, London W1H 7AL . 2. Going concern The financial statements have been prepared on a going concern basis inaccordance with applicable United Kingdom Accounting Standards.The directors have adopted this basis as they consider that the company hassufficient working capital to meet its obligations as they fall due.Chiddingfold Investments Limited, has agreed to fund the company's workingcapital requirements for a period until 30 June 2006, to the extent that suchcosts are not covered by other fund raisings or reverse acquisitiontransactions.During the year the Company made losses of ‚£345,000 and had net liabilities at31 December 2004 of ‚£69,000.The directors continue to actively seek suitable targets for a reverseacquisition.The directors have therefore prepared the financial statements on the goingconcern basis. The financial statements do not include any adjustments thatmight arise if this basis was inappropriate. 3. Basis of consolidation The consolidated financial statements include the financial statements of theCompany and have been prepared using both merger accounting principles andacquisition accounting principles.The Company has not presented its own profit and loss account as permitted bySection 230(3) of the Companies Act 1985. The Company's loss for the financialyear was ‚£345,000.4. Loss per shareLoss per share are calculated on a net basis using the loss on ordinaryactivities and the weighted average number of shares detailed below.In calculating fully diluted loss per share, the weighted average number ofshares is adjusted for the effect of dilutive share options issued under Groupshare option schemes. 2004 2003 ‚£'000 ‚£'000 Basic and diluted losses attributable to ordinary (345) (150)shareholders Number Number Weighted average number of ordinary shares 39,767,965 3,625,812 Dilutive share options - - Adjusted weighted average number of ordinary shares 39,767,965 3,625,812 Loss per share (0.86p) (4.14p) Fully diluted loss per share (0.86p) (4.14p) 5. Reconciliation of operating loss to net cash outflow from operating activities 2004 2003 ‚£'000 ‚£'000 Operating loss (345) (76) Decrease in debtors - 48 Increase/(decrease) in creditors 31 (48) Creditor settled via issue of shares 89 - Net cash outflow from operating activities (225) (76) 6. Reserves Share Profit and Total premium loss account account ‚£'000 ‚£'000 ‚£'000 At 1 January 2004 10,241 (15,478) (5,237) Loss for the year - (345) (345) Issue of shares 38 - 38 At 31 December 2004 10,279 (15,823) (5,544) 7. Taxation Factors affecting taxation:The tax charge for the year does not equate to the loss before tax at thestandard rate of corporation tax in the United Kingdom (30%). The differencesare explained below: 2004 2003 ‚£'000 ‚£'000 Loss on ordinary activities before taxation (345) (150) Loss on ordinary activities multiplied by the (104) (45)standard rate of corporation tax in the United Kingdom of 30% (2003: 30%) Effect of non-deductible expenses and addition to 104 45tax losses - - At 31 December 2004, the company had accumulated tax losses of ‚£817,627 arisingform management expenses and ‚£1,476,749 of capital losses. 8. Dividends The Directors are not proposing the payment of a dividend in respect of theyear ended 31 December, 2004.ENDAZURE HOLDINGS PLC
Date   Source Headline
13th Sep 20179:34 amRNSHardman Research: GeneICE and VAL101 progress
7th Sep 20177:00 amRNSGeneICE & VAL101 Update
11th Aug 20177:00 amRNSConvertible Loan Facility
2nd Aug 20177:00 amRNSConversion of Loan Note
28th Jul 20177:00 amRNSLicencing Agreement
22nd Jun 20177:00 amRNSFormation of & Appointments to an Advisory Board
15th Jun 20177:00 amRNSValiSeek Development Update - Recruitment Closes
1st Jun 201711:00 amRNSYorkville CLN Conversion
31st May 201711:00 amRNSHardman Research:Developing novel cancer therapies
30th May 201710:34 amRNSResult of AGM
24th May 20177:00 amRNSNOTIFICATION OF AUSTRALIAN PATENT ALLOWANCE
5th May 20175:28 pmRNSNotice of AGM
5th May 20177:00 amRNSFinal Results
27th Apr 201710:07 amRNSRe: SHARES Magazine Supplement on ValiRx website
19th Apr 20179:00 amRNSChange of Registered Office
15th Mar 20179:33 amRNSDirector/PDMR Shareholding
8th Mar 20177:00 amRNSValiSeek Clinical Development Update
2nd Mar 20177:00 amRNSDirector/PDMR Shareholding
1st Mar 20171:37 pmRNSPlacing to raise £1.16m and Proposed Subscription
28th Feb 20177:00 amRNSPublication of Peer-Reviewed Articles on VAL401
11th Jan 20177:00 amRNSCLINICAL TRIAL UPDATE - Positive VAL201 Results
30th Dec 20167:00 amRNSYorkville CLN Conversion
8th Dec 20167:00 amRNSEuropean Patent Granted for Lead Compound VAL201
2nd Dec 20164:15 pmRNSConvertible Loan Facility
1st Dec 20167:00 amRNSValiSeek Clinical Development Update
29th Nov 20167:00 amRNSQuarterly Update on Clinical Developments
3rd Nov 20167:00 amRNSValiSeek Clinical Development Update
28th Oct 20169:00 amRNSCorporate Video re Clinical Status Q4, 2016
25th Oct 20167:00 amRNSPatent Update
13th Oct 20164:20 pmRNSHolding(s) in Company
13th Oct 20164:20 pmRNSHolding(s) in Company
13th Oct 20167:00 amRNSUpdate on Recent Presentations
12th Oct 201611:15 amRNSResult of General Meeting
5th Oct 20163:42 pmRNSCLN Conversion
28th Sep 201611:09 amRNSNotice of GM
27th Sep 20167:00 amRNSHalf-year Report
26th Sep 20167:00 amRNSValiRx selected for The Parliamentary Review 2016
13th Sep 20167:00 amRNSQuarterly Update on Clinical Developments
2nd Sep 20162:10 pmRNSPlacing, issue of warrants & Convertible Loan
11th Aug 20167:00 amRNSValiSeek Clinical Development Update
4th Aug 201611:32 amRNSIssue of Equity
28th Jul 20167:00 amRNSNotification of New Zealand Patent Grant Allowance
26th Jul 20167:00 amRNSIssue of Equity and Bracknor Facility Update
14th Jul 20167:00 amRNSValiSeek Clinical Development Update
12th Jul 201611:58 amRNSResult of GM
7th Jul 20167:00 amRNSSale of TRAC Technology Rights for EUR 0.8 million
27th Jun 20167:00 amRNSNotice of GM
20th Jun 20162:24 pmRNSResult of AGM
7th Jun 20167:00 amRNSQuarterly Update
7th Jun 20167:00 amRNSAppointment of Joint Broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.